Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000020916 | SCV000745459 | pathogenic | GNPTG-mucolipidosis | 2015-09-21 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000020916 | SCV000794799 | pathogenic | GNPTG-mucolipidosis | 2017-10-17 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000020916 | SCV002045556 | pathogenic | GNPTG-mucolipidosis | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001699180 | SCV003443015 | pathogenic | not provided | 2023-10-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg66*) in the GNPTG gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNPTG are known to be pathogenic (PMID: 19370764, 20301784). This variant is present in population databases (rs193302848, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with mucolipidosis type III gamma (PMID: 15060128, 28950892). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 21713). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV000020916 | SCV000041523 | not provided | GNPTG-mucolipidosis | no assertion provided | literature only | ||
Clinical Genetics, |
RCV001699180 | SCV001925987 | pathogenic | not provided | no assertion criteria provided | clinical testing |